BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 35570281)

  • 1. What are the prospects for the hormonal IUD in the public sector? A mixed-method study of the user population in Zambia.
    Brunie A; Lydon M; Stankevitz K; Chintu N; Brennan C; Danna K; Rademacher KH
    BMC Womens Health; 2022 May; 22(1):178. PubMed ID: 35570281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors affecting uptake of the levonorgestrel-releasing intrauterine device: A mixed-method study of social franchise clients in Nigeria.
    Brunie A; Nwala AA; Stankevitz K; Lydon M; Danna K; Afolabi K; Rademacher KH
    PLoS One; 2021; 16(9):e0257769. PubMed ID: 34587200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canadian Contraception Consensus (Part 1 of 4).
    Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N;
    J Obstet Gynaecol Can; 2015 Oct; 37(10):936-42. PubMed ID: 26606712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanding long-acting contraceptive options: a prospective cohort study of the hormonal intrauterine device, copper intrauterine device, and implants in Nigeria and Zambia.
    Brunie A; Stankevitz K; Nwala AA; Nqumayo M; Chen M; Danna K; Afolabi K; Rademacher KH
    Lancet Glob Health; 2021 Oct; 9(10):e1431-e1441. PubMed ID: 34474001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canadian Contraception Consensus (Part 2 of 4).
    Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N
    J Obstet Gynaecol Can; 2015 Nov; 37(11):1033-9. PubMed ID: 26629725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
    Bahamondes L; Brache V; Meirik O; Ali M; Habib N; Landoulsi S;
    Hum Reprod; 2015 Nov; 30(11):2527-38. PubMed ID: 26409014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contraceptive Continuation and Experiences Obtaining Implant and IUD Removal Among Women Randomized to Use Injectable Contraception, Levonorgestrel Implant, and Copper IUD in South Africa and Zambia.
    Cartwright AF; Callahan RL; Beksinska M; Kasaro MP; Tang JH; Milford C; Wong C; Velarde M; Maphumulo V; Fawzy M; Chinyama M; Chabu E; Mudenda M; Smit J
    Stud Fam Plann; 2023 Jun; 54(2):379-401. PubMed ID: 36727169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormonal intrauterine devices.
    Rybo G; Andersson K; Odlind V
    Ann Med; 1993 Apr; 25(2):143-7. PubMed ID: 8489751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives.
    Modesto W; Bahamondes MV; Bahamondes L
    Hum Reprod; 2014 Jul; 29(7):1393-9. PubMed ID: 24812309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study.
    Luukkainen T; Allonen H; Haukkamaa M; Holma P; Pyörälä T; Terho J; Toivonen J; Batar I; Lampe L; Andersson K
    Contraception; 1987 Aug; 36(2):169-79. PubMed ID: 3123132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties.
    Luukkainen T; Toivonen J
    Contraception; 1995 Nov; 52(5):269-76. PubMed ID: 8585882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of the levonorgestrel-releasing IUD: its advantages and disadvantages when compared to the copper-releasing IUDs.
    Chi IC
    Contraception; 1991 Dec; 44(6):573-88. PubMed ID: 1773615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuation rates of long-acting methods of contraception. A comparative study of Norplant implants and intrauterine devices.
    Fleming D; Davie J; Glasier A
    Contraception; 1998 Jan; 57(1):19-21. PubMed ID: 9554246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system.
    Suvisaari J; Lähteenmäki P
    Contraception; 1996 Oct; 54(4):201-8. PubMed ID: 8922872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sexual behaviour among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Data from the ECHO randomized trial.
    Hofmeyr GJ; Singata-Madliki M; Batting J; Steyn P; Thomas KK; Issema R; Beesham I; Mbatsane E; Morrison C; Deese J; Smit J; Philip N; Palanee-Phillips T; Reddy K; Onono M; Mastro TD; Baeten JM;
    PLoS One; 2024; 19(5):e0299802. PubMed ID: 38722832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices.
    Sivin I; Stern J; Diaz J; Diaz MM; Faundes A; el Mahgoub S; Diaz S; Pavez M; Coutinho E; Mattos CE
    Contraception; 1987 Mar; 35(3):245-55. PubMed ID: 3111785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
    Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium
    Lancet; 2019 Jul; 394(10195):303-313. PubMed ID: 31204114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Introducing the hormonal Intrauterine Device in Madagascar, Nigeria, and Zambia: results from a pilot study.
    Danna K; Jaworski G; Rahaivondrafahitra B; Rasoanirina F; Nwala A; Nqumayo M; Smith G; Moon P; Jackson A; Thurston S; Kalamar A
    Reprod Health; 2022 Jan; 19(1):4. PubMed ID: 34991651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of menorrhagia with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
    Wildemeersch D; Schacht E
    Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):93-101. PubMed ID: 11518454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential user interest in new long-acting contraceptives: Results from a mixed methods study in Burkina Faso and Uganda.
    Callahan RL; Brunie A; Mackenzie ACL; Wayack-Pambè M; Guiella G; Kibira SPS; Makumbi F
    PLoS One; 2019; 14(5):e0217333. PubMed ID: 31136612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.